4QQN

Protein arginine methyltransferase 3 in complex with compound MTV044246

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.08 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.183 
  • R-Value Observed: 0.184 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history. 


Literature

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3).

Kaniskan, H.U., Eram, M.S., Zhao, K., Szewczyk, M.M., Yang, X., Schmidt, K., Luo, X., Xiao, S., Dai, M., He, F., Zang, I., Lin, Y., Li, F., Dobrovetsky, E., Smil, D., Min, S.J., Lin-Jones, J., Schapira, M., Atadja, P., Li, E., Barsyte-Lovejoy, D., Arrowsmith, C.H., Brown, P.J., Liu, F., Yu, Z., Vedadi, M., Jin, J.

(2018) J Med Chem 61: 1204-1217

  • DOI: 10.1021/acs.jmedchem.7b01674
  • Primary Citation of Related Structures:  
    4QQN

  • PubMed Abstract: 

    • PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4 ...

    PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4. Here, we report comprehensive structure-activity relationship studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated in the discovery of 4 and other highly potent (IC 50 values: ∼10-36 nM), selective, and cell-active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37). In addition, we generated compounds that are very close analogs of these potent inhibitors but displayed drastically reduced potency as negative controls (compounds 49-51). These inhibitors and negative controls are valuable chemical tools for the biomedical community to further investigate biological functions and disease associations of PRMT3.

    Organizational Affiliation: 

    Center for Chemical Biology and Drug Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
PRMT3 protein A340Homo sapiensMutation(s): 0 
Gene Names: PRMT3, HRMT1L3
EC: 2.1.1
Find proteins for O60678 (Homo sapiens)
Explore O60678 
Go to UniProtKB:  O60678
NIH Common Fund Data Resources
PHAROS:  O60678
GTEx:  ENSG00000185238
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.08 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.183 
  • R-Value Observed: 0.184 
  • Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 70.319α = 90
b = 70.319β = 90
c = 172.918γ = 90
Software Package:
Software NamePurpose
SCALEPACKdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction
HKL-3000data reduction
HKL-3000data scaling
MOLREPphasing
Cootmodel building

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2014-09-17
    Type: Initial release
  • Version 1.1: 2018-05-16
    Changes: Data collection, Database references